| Today’s Big NewsJun 10, 2024 |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now. 
|
|
| By Annalee Armstrong Moderna’s combo flu and COVID-19 vaccine zipped through a late-stage trial this winter, and the results are showing a higher immune response than licensed comparators—including the famed biotech’s own Spikevax. |
|
|
|
By Fraiser Kansteiner SpringWorks has received a notice of termination on an amended collaboration and licensing deal with GSK from 2022. Under the updated pact, GSK and SpringWorks were working together to develop and potentially market combinations of Blenrep and Ogsiveo in multiple myeloma. |
By Nick Paul Taylor The biopharma industry is entering the second half of the year with a spring in its step. After seeing pessimism engulf the sector in 2023, GlobalData found healthcare industry professionals had a sunnier disposition as they assessed their growth prospects in its latest survey. |
By Zoey Becker The company expects to introduce brigimadlin in dedifferentiated liposarcoma and zongertinib in HER2-mutated non-small cell lung cancer next year. The launches are part of the company's wider plan to bring 25 new products to the market by 2030. |
|
Wednesday, June 26, 2024 | 2pm ET/ 11am PT In this webinar, we outline a patient-centered telehealth genetic counseling model that accelerates time to meet recruitment goals by engaging and recruiting genetically eligible participants. Certified genetic counselors are uniquely qualified to support the development of a multi-phased approach to patient identification and screening, disclose genetic test results, and more. Register now. 
|
|
By Conor Hale Abbott's new Libre Rio and Lingo wearable sensors are aimed at the growing health and wellness market, as well as people with Type 2 diabetes that are not taking insulin. |
By Zoey Becker Construction at the Sanford site, which will employ more than 100 people, will kick off later this year and should wrap up by 2027, the company said. |
By James Waldron Not content with bringing in one of the largest private biotech fundraises of 2024 so far, Alumis has now become the latest drug developer to set its sights on the public markets. |
By Fraiser Kansteiner The FDA approved Arexvy for RSV prevention in adults ages 50 to 59 who are at increased risk of developing RSV disease. The green light marks Arexvy’s first new approval since the vaccine’s original nod to prevent lower respiratory tract disease caused by RSV in adults ages 60 and older last May. |
By James Waldron Skye Bioscience’s share price tumbled in pre-market trading Monday, as the biotech announced a strategic refocus in the wake of a phase 2 trial failure. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report. |
|
|---|
|
|
|
Biotech companies must be able to navigate the complexities of development and approval. Learn how to drive improved speed, quality, predictability, and risk management by making key changes. Download now for exclusive insights. 
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
